BC Extra | Dec 3, 2019
Financial News

Alphamab Oncology sets sights on $220M IPO as HKSE continues to gain momentum

Alphamab Oncology is aiming to raise about HK$1.7 billion ($221.1 million) in an IPO on the Hong Kong stock exchange next week in an offering that would value the company at HK$8.7 billion if priced...
BC Extra | Jul 15, 2019
Financial News

July 15 Financial Quick Takes: RA raises $300M for new fund; plus Alphamab and Castle

RA launches $300M VC fund  RA Capital raised $300 million for its first close-ended venture fund, dubbed Nexus, which will invest in private companies backed by the firm's main fund, RA Capital Healthcare Fund L.P....
BioCentury | Nov 21, 2018
Finance

Alphamab's cancer cash

Alphamab Oncology spun out from Suzhou Alphamab Co. Ltd. and raised more than $100 million in a series A round to advance multiple cancer biologics through clinical testing. Investors in the round, which closed on...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD); organ transplant rejection; renal transplant rejection Mouse and non-human primate studies suggest inhibiting CD122 could enhance the efficacy of Nulojix belatacept to treat GvHD, skin graft rejection and renal transplant rejection....
BC Innovations | Jan 4, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Animal models An allogeneic macaque model of HSCT-associated GvHD could be used to screen for therapies. Transplant of HSCs between pairs of allogeneic cynomolgus macaques that harbored matching major histocompatibility complex (MHC) alleles at...
BC Week In Review | Nov 2, 2015
Company News

Bristol-Myers sales and marketing update

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that Nulojix belatacept from Bristol-Myers Squibb has “considerable added benefit” in preventing kidney transplant rejection. The agency had assessed the...
BC Week In Review | Feb 18, 2013
Clinical News

Nulojix belatacept regulatory update

Bristol-Myers and Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) said they reached an agreement on the price for Nulojix belatacept to prevent organ rejection in adult kidney transplant patients - its approved indication. According to the...
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer  A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
BC Extra | Dec 6, 2012
Politics & Policy

Pricing negotiations under AMNOG completed for 12 drugs

Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) said pricing negotiations under drug pricing law AMNOG have been completed for 12 drugs. For 11 drugs, GKV-Spitzenverband and drug sponsors reached an agreement on a price; the...
BioCentury | Jul 16, 2012
Regulation

Rating innovation

The French and German reimbursement systems use the same definition of pharmaceutical innovation: additional medical benefit versus a comparator. But differences in each approach mean the outcomes will not always be the same. According to...
Items per page:
1 - 10 of 57